Pre-Test Relapsed/ Refractory Multiple Myeloma: Novel and Cellular Therapies in 2023 Pre-Test Which of the following statements are true regarding the BOSTON clinical trial of selinexor in patients with R/R MM? Enrolled patients had received 4 or more prior lines of therapy Median PFS of the selinexor arm was nearly 50% higher than standard treatment Patients received selinexor in combination with pomalidomide and dexamethasone Treatment with selinexor combination includes warnings for myocardial infarction Unsure Which of the following therapeutic agents under investigation for patients with R/R MM is a bi-specific antibody that targets CD3 and GPRC5D receptors? elranatamab linvoseltamab pacanalotamab talquetamab Unsure Which of the following is the most common grade 3–4 adverse event in patients treated with selinexor for R/R MM? hyponatremia peripheral neuropathy nausea thrombocytopenia Unsure How confident are you in your ability to effectively sequence treatments for patients with R/R MM? Very confident Confident Somewhat confident Not very confident Not at all confident
